Uncategorized
Neurotech’s macular telangiectasia treatment sees positive phase 2 results
A phase 2 trial of NT-501 found the therapy had a beneficial effect in patients with macular telangiectasia type 2, according to a press release from Neurotech Pharmaceuticals.Patients in the multicenter, randomized clinical trial had a statistically significant reduction in the progressive loss of photoreceptors in treated vs. untreated eyes at 24 months, the release said.